IDDI: Pioneering the Future of Clinical Research

Clinical biostatistics isn’t just what we do best — it’s who we are. Inspired by our Founder and Chief Scientific Officer, Marc Buyse, ScD, and our main expert in biostatistics, Tomasz Burzykowski, Ph.D., IDDI has and always will be at the forefront in new research methods. 

We collaborate with leading academic institutions and key opinion leaders (KOLs) on new statistical research methods and insights ensuring we stay at the leading edge of clinical practice.

Clinical Research Projects  

IDDI devotes a portion of our revenue to the deployment of advanced statistical methodology, including:

IDDI — in partnership with Bristol Myers Squibb, the EORTC, the UCL, the University Hospital and Cancer Center of Lyon, and with the financial support of the Walloon Region, Biowin — developed Generalized Pairwise Comparisons (GPC), a new statistical methodology that combines statistical soundness with the inclusion of patient preferences, thereby paving the way to personalized medicine. After investing in this project for some years, IDDI launched in July 2023 One2Treat, a company whose mission is to develop methods and advanced software that enable a holistic evaluation of treatment effects by integrating all key patient-relevant outcomes into a single comprehensive assessment of the Net Treatment Benefit.

In 2017, IDDI partnered with Biowin, the Walloon cluster of biotechnology, to analytically and clinically validate a CE-marked in vitro diagnostic kit based on a DNA methylation signature predicting the benefit from neoadjuvant anthracycline/taxane chemotherapy in previously untreated, non-metastatic, primary triple negative breast cancer patients. 

IDDI Will Perform the Clinical Validation of the Signature:

  • Designed, set up, analyzed, and reported the retrospective study 
  • Designed the prospective 
  • Statistically supported for signature fine-tuning and kit analytical validation 

The BRAVO project was granted by EuroTransBio to IDDI in collaboration with Pamgene, VUMC, and I-Biostat. 

IDDI, with the financial support of the Walloon Region, Biowin, developed a statistical software for Statistical Monitoring Applied to Research Trials (SMART) to detect heterogeneity of data across investigational centers and to create a quality label for clinical trial data. After investing in this project for over a decade, IDDI launched CluePoints in early 2012, offering a unique Central Statistical Monitoring tool.  

Trust Your Data to IDDI

Start Now